Background: Chronic kidney disease (CKD) is a slow and progressive loss of

kidney function over a period of several years. CKD includes various causes like diabetes,

hypertension, infection, inflammation, malignancy and genetics which damage the kidneys

and decrease the glomerular filtration rate (GFR). Beta human chorionic gonadotropin (β-

HCG) is synthesized by the syncytiotrophoblasts of the placenta during pregnancy. β-HCG

shows sensitivity for choriocarcinoma, hydatidiform mole and testicular tumours, but its

level is also high in chronic renal disorder. Our study was aimed to assess and compare the

status of serum β-HCG level in chronic kidney disease subjects and healthy controls.

Materials and Methods: The case-control study was conducted on 220 CKD patients.

Cases (n = 220) were selected from the Medical OPD and ward of Jawahar Lal Nehru

Medical College and Associated Group of Hospitals, Ajmer. Age and sex-matched healthy

controls (n = 100) were selected from MOPD. The present study was approved by

Institutional Ethical Committee. Overnight fasting venous blood sample was collected from

all the participants under aseptic precautions for the estimation of biochemical parameters.

Results: The mean activity of Serum β-HCG was significantly higher in CKD patients as

compared to healthy controls (p < 0.0001). Positive pearson correlation of serum creatinine

with serum β-HCG was found (r= 0.73). Conclusion: Serum β-HCG can be used as a

biomarker for the early detection of CKD in the general population to prevent the morbidity

and mortality which are associated with CKD. If CKD is detected early and managed

appropriately the deterioration in kidney functions can be slowed and the risk of

cardiovascular diseases in renal patients can be reduced.